DaVita healthCare Partners Inc Stock News

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $133.73, denoting a +0.09% change from the preceding trading day.

Similar to the six vital nutrients required for good health, we have examined the six pillars that support the economy and zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a h

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.

Coca-Cola has a dividend yield that's more than double that of the S&P 500. Moody's has a large market share of the credit ratings segment.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

IMMR, NVR, SKWD, DVA and APAM have been added to the Zacks Rank #1 (Strong Buy) List on March 14, 2024.

IMXI, SKWD and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 14, 2024.

DENVER , March 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will p

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.